Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 2/2016

01-06-2016 | case report

Endometrial cancer treated with levonorgestrel-releasing intrauterine device for almost three years in an elderly woman with comorbidity

Authors: Lisbeth Anita Andreasen, M.D., Sofie Leisby Antonsen, M.D., Ph.D, Annette Settnes, M.D., Ph.D

Published in: memo - Magazine of European Medical Oncology | Issue 2/2016

Login to get access

Summary

In this case report we describe the treatment of a 95-year-old woman with endometrioid adenocarcinoma. She suffered from cardiovascular comorbidity and did not want surgical treatment. Instead a levonorgestrel-releasing intrauterine device (Mirena) was inserted. She had progression of the tumor but with a minimum of symptoms and side effects. At the final examination there were no signs of extra uterine disease. The levonorgestrel-releasing intrauterine device may be an acceptable alternative to surgery in severely comorbid patients, or if the patient refuses surgical treatment.
Literature
1.
Bovicelli A, D’Andrilli G, Giordano A, De Iaco P. Conservative treatment of early endometrial cancer. J Cell Physiol. 2013;228(6):1154–8. doi:10.1002/jcp.24292.CrossRefPubMed
2.
Ruan X, Mueck AO. Systemic progesterone therapy – oral, vaginal, injections and even transdermal? Maturitas. 2014;79(3):248–55. doi:10.1016/j.maturitas.2014.07.009.CrossRefPubMed
3.
Gunderson CC, Fader AN, Carson KA, Bristow RE. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol. 2012;125(2):477–82. doi:10.1016/j.ygyno.2012.01.003.CrossRefPubMed
4.
Kim MK, Seong SJ, Kim YS, et al. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer. Am J Obstet Gynecol. 2013;209(4):358.e1–358.e4. doi:10.1016/j.ajog.2013.06.031.CrossRef
5.
Perri T, Korach J, Gotlieb WH, et al. Prolonged conservative treatment of endometrial cancer patients: more than 1 pregnancy can be achieved. Int J Gynecol Cancer. 2011;21(1):72–8. doi:10.1097/IGC.0b013e31820003de.CrossRefPubMed
6.
Montz FJ, Bristow BE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002;186:651–7.CrossRefPubMed
7.
Giannopoulos T, Butler-Manuel S, Tailor A. Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma. Gynecol Oncol. 2004;95(3):762–4.CrossRefPubMed
8.
Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol. 2005;97(3):924–7, Jun.CrossRefPubMed
Metadata
Title
Endometrial cancer treated with levonorgestrel-releasing intrauterine device for almost three years in an elderly woman with comorbidity
Authors
Lisbeth Anita Andreasen, M.D.
Sofie Leisby Antonsen, M.D., Ph.D
Annette Settnes, M.D., Ph.D
Publication date
01-06-2016
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 2/2016
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-016-0266-4

Other articles of this Issue 2/2016

memo - Magazine of European Medical Oncology 2/2016 Go to the issue

review

Initial emergencies in children and adolescents with malignant hematologic–oncological diseases

short review

Circulating tumor cells and circulating tumor DNA in colon cancer

case report

Intravascular large B‑cell lymphoma

short review

CDK4/6 inhibition in luminal breast cancer

short review

Immunotherapy for head and neck squamous cell carcinoma

comment

Is there room for chemotherapy in elderly patients with metastatic castration-resistant prostate cancer (mCRPC) in the era of targeted hormone therapy?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits